Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Author(s):

Key Takeaways

Recently released publications reveal evidence that rituximab leads to increased relapse rates relative to novel targeted therapies.
The clinical significance of these findings emphasizes personalized treatment strategies, offering improved disease management and patient care.
In practice, these data support the integration of novel therapies into standard protocols, aligning with observed improvements in patient outcomes.

Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have led to increased relapse rates.

Now Viewing

EP: 1.Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

EP: 2.Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

EP: 3.Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management

EP: 4.NMOSD Management with New FDA-approved Agents to Reduce Relapse and Hospitalization Rates

Video content above is prompted by the following:

Briefly review the current treatment landscape for aquaporin-4 IgG–seropositive (AQP4-IgG+) NMOSD and the role of anti-CD20 therapies, particularly rituximab.
Could you speak to the clinical significance of these findings and their implications for the neurology community?
How do these data compare to what you see in your clinical practice?